Application of genotype-guided cancer therapy in solid tumors

Pharmacogenomics

Volumn 15, Issue 1, 2014, Pages 79-93

  Patel, Jai N ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Cancer; Genetics; Genotype; Pharmacogenetics; Therapy; Tumors

Indexed keywords

B RAF KINASE; CETUXIMAB; CRIZOTINIB; CYTOCHROME P450 2D6; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIRTECAN; FLUOROURACIL; IMATINIB; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB; PLACEBO; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VEMURAFENIB;

BREAST CANCER; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CUTANEOUS MELANOMA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL ETHICS; NEUTROPENIA; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECURRENCE RISK; REVIEW; SEQUENCE ANALYSIS; SOLID TUMOR; SOMATIC MUTATION; STOMACH CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84890506558     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.227     Document Type: Review

References (97)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
2. Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: background, methodology, and clinical adoption of pharmacogenetics. Oncologist 16(6), 811-819 (2011).
3. Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta 1603(2), 99-111 (2003). (Pubitemid 36262943)
4. Wang L, Mcleod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011).
5. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10(8), 825-833 (2009).
6. Irvin WJ Jr, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24), 3232-3239 (2011).
7. Madlensky L, Natarajan L, Tchu S et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89(5), 718-725 (2011).
8. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007). (Pubitemid 47555336)
9. Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl Cancer Inst. 104(6), 441-451 (2012).
10. Rae JM, Drury S, Hayes DF et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl Cancer Inst. 104(6), 452-460 (2012).
11. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl Cancer Inst. 104(16), 1264; author reply 1266-1268 (2012).
12. Dezentje VO, van Schaik RH, Vletter-Bogaartz JM et al. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res. Treat. 140(2), 363-373 (2013).
13. Ahmad A, Ali SM, Ahmad MU, Sheikh S, Ahmad I. Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res. Treat. 122(2), 579-584 (2010).
14. Seck K, Riemer S, Kates R et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. 11(16), 5886-5892 (2005). (Pubitemid 41170317)
15. van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12(7), 555-558 (2002). (Pubitemid 35177085)
16. van Kuilenburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6(12), 4705-4712 (2000). (Pubitemid 32110408)
17. Toffoli G, Cecchin E. Pharmacogenetics and stomach cancer: an update. Pharmacogenomics 8(5), 497-505 (2007). (Pubitemid 46746357)
18. Deenen MJ, Cats A, Sechterberger MK, Severens JL, Smits PHM. Safety, pharmacokinetics (PK), and cost effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. J. Clin. Oncol. 29(Suppl.), Abstract 3606 (2011).
19. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer 43(6), 1011-1016 (2007). (Pubitemid 46483039)
20. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy 28(6), 755-768 (2008). (Pubitemid 351975379)
21. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A128 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007). (Pubitemid 47394168)
22. Marcuello E, Paez D, Pare L et al. Agenotype-directed PhaseI-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br. J. Cancer 105(1), 53-57 (2011).
23. Toffoli G, Cecchin E, Gasparini G et al. Genotype-driven PhaseI study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(5), 866-871 (2010).
24. Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res. 11(10), 3778-3783 (2005). (Pubitemid 40685596)
25. Villafranca E, Okruzhnov Y, Dominguez MA et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19(6), 1779-1786 (2001). (Pubitemid 32230880)
26. Tan BR, Thomas F, Myerson RJ et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J. Clin. Oncol. 29(7), 875-883 (2011).
27. Mehta VK, Cho C, Ford JM et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 55(1), 132-137 (2003). (Pubitemid 36020352)
28. Klautke G, Feyerherd P, Ludwig K, Prall F, Foitzik T, Fietkau R. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br. J. Cancer 92(7), 1215-1220 (2005). (Pubitemid 40604394)
29. Mohiuddin M, Winter K, Mitchell E et al. Randomized Phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J. Clin. Oncol. 24(4), 650-655 (2006). (Pubitemid 46630429)
30. Iles S, Gollins S, Susnerwala S et al. Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a PhaseI/II study. Br. J. Cancer 98(7), 1210-1216 (2008). (Pubitemid 351481677)
31. Patel JN, Fuchs CS, Ozwar K, Chen Z, McLeod HL. Gastric cancer pharmacogenetics: progress or old tripe? Pharmacogenomics 14(9), 1053-1064 (2013).
32. Hancock L. The inhibition of anaplastic lymphoma kinase in non-small cell lung tumours with the ALK rearrangement may result in tumour shrinkage. Thorax doi:10.1136/thx.2011.159467 (2011) (Epub ahead of print).
33. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010).
34. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1 study. Lancet Oncol. 13(10), 1011-1019 (2012).
35. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385-2394 (2013).
36. Mosse YP, Lim MS, Voss SD et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group Phase 1 consortium study. Lancet Oncol. 14(6), 472-480 (2013).
37. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002). (Pubitemid 34716871)
38. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
39. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366(3), 207-215 (2012).
40. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694-1703 (2012).
41. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33(5), 459-465 (2002). (Pubitemid 34747864)
42. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626-632 (2008). (Pubitemid 351264358)
43. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 26(33), 5360-5367 (2008).
44. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
45. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327-3334 (2013).
46. Katakami N, Atagi S, Goto K et al. LUX-Lung 4: a Phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31(27), 3335-3341 (2013).
47. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005). (Pubitemid 41464705)
48. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Gepar Quattro study. J. Clin. Oncol. 28(12), 2024-2031 (2010).
49. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006). (Pubitemid 46021510)
50. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012).
51. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
52. Bang YJ, van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010).
53. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010).
54. van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011).
55. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med. Decis. Making 30(3), 328-340 (2010).
56. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28(16), 2777-2783 (2010).
57. Ragoussis J. Genotyping technologies for genetic research. Annu. Rev. Genomics Hum. Genet. 10, 117-133 (2009).
58. Frey LJ, Piccolo SR, Edgerton ME. Multiplicity: an organizing principle for cancers and somatic mutations. BMC Med. Genomics 4, 52 (2011).
59. Stanek EJ, Sanders CL, Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450-458 (2012).
60. McKinnon RA, Ward MB, Sorich MJ. Acritical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. 3(5), 751-759 (2007). (Pubitemid 350162075)
61. Vijverberg SJ, Pieters T, Cornel MC. Ethical and social issues in pharmacogenomics testing. Curr. Pharm. Des. 16(2), 245-252 (2010).
62. Lipton P. Pharmacogenetics: the ethical issues. Pharmacogenomics J. 3(1), 14-16 (2003). (Pubitemid 36432462)
63. Rothstein MA. Is GINA worth the wait? J. Law Med. Ethics 36(1), 174-178 (2008).
64. Hudson KL. Genomics, health care, and society. N. Engl. J. Med. 365(11), 1033-1041 (2011).
65. Warner AW, Bhathena A, Gilardi S et al. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Clin. Pharmacol. Ther. 89(4), 529-536 (2011).
66. McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339(6127), 1563-1566 (2013).
67. Deverka PA, Vernon J, McLeod HL. Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 50, 423-437 (2010).
68. Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11(6), 507-509 (2010).
69. Pirker R, Herth FJ, Kerr KM et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J. Thorac. Oncol. 5(10), 1706-1713 (2010).
70. Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J. Clin. Oncol. 30(27), 3330-3336 (2012).
71. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011).
72. Frueh FW, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008).
73. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
74. Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91(3), 249-258 (2005). (Pubitemid 40903087)
75. Irvin WJ Jr, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24), 3232-3239 (2011).
76. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother. Pharmacol. 60(4), 503-507 (2007). (Pubitemid 47084259)
77. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin. Cancer Res. 5(10), 2672-2673 (1999). (Pubitemid 29493937)
78. Thomas F, Hoskins JM, Dvorak A, Tan BR, McLeod HL. Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics 11(12), 1751-1756 (2010).
79. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55(7), 1407-1412 (1995).
80. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004). (Pubitemid 41103619)
81. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561-566 (2007). (Pubitemid 47206930)
82. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344(14), 1052-1056 (2001). (Pubitemid 32267975)
83. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440), 1127-1134 (2004). (Pubitemid 39296599)
84. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
85. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004). (Pubitemid 38720929)
86. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
87. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J. Natl Cancer Inst. 103(3), 250-263 (2011).
88. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence insitu hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 5(1), 63-69 (2004). (Pubitemid 38821193)
89. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229(4717), 974-976 (1985). (Pubitemid 16248488)
90. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann. Surg. Oncol. 17(4), 1168-1176 (2010).
91. Bos JL, Fearon ER, Hamilton SR et al. Prevalence of RAS gene mutations in human colorectal cancers. Nature 327(6120), 293-297 (1987). (Pubitemid 17075079)
92. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10(7), 461-466 (2005). (Pubitemid 41266326)
93. Johnson JR, Cohen M, Sridhara R et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res. 11(18), 6414-6421 (2005). (Pubitemid 41338977)
94. Gao G, Ren S, Li A et al. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from 6 Phase III randomized controlled trials. Int. J. Cancer 31(5), E822-E829 (2011).
95. US FDA. Table of Pharmacogenomic Biomarkers in Drug Labels (2010).www.fda.gov/%20drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm
96. PharmGKB. www.pharmgkb.org
97. My Cancer Genome. www.mycancergenome.org